Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jul 25, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure," is looking at how safe and effective a shorter course of antibiotics can be after surgery for appendicitis, whether it's simple or complicated. The goal is to see if patients can recover well with less antibiotic use, which may help reduce side effects and antibiotic resistance.
To be eligible for this study, participants need to be at least 18 years old and scheduled for an appendectomy, which is surgery to remove the appendix. However, there are some people who can't join, such as those who are pregnant, have certain medical conditions like severe heart failure or active cancer, or are currently taking other antibiotics. If you join the trial, you can expect regular follow-ups after your surgery to monitor your recovery and any effects from the antibiotics. This study is currently recruiting participants, so if you're interested, it might be a good opportunity to contribute to important research while also receiving care for appendicitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Age ≥ 18 years
- • Planned appendectomy (laparoscopic or open)
- • Working telephone number or reliable method to contact patient after hospital discharge
- Exclusion Criteria:
- • Unable to consent
- • Pregnant Women
- • Prisoners
- • Immunocompromised as determined by clinical team, or patients actively receiving steroids, chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic malignancy affecting the immune system, leukopenia, or end-stage AIDS
- • Heart failure
- • Allergy to bupivacaine
- • Unlikely to comply with treatment or follow-up
- • Inpatient consultation for appendicitis
- • Clinically suspected of sepsis based on Sepsis-3 definition
- • Current use of antibiotics for other indications
- • Type 1 Diabetes or uncontrolled hyperglycemia
- • Surgeon preference
- • Patient preference
- • Research team unavailable
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Lucy Kornblith, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported